🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMetabolic Health & DiabetesSURPASS-CVOT: tirzepatide cardiovascular outcomes trial design — anyone have experience? Page 4

SURPASS-CVOT: tirzepatide cardiovascular outcomes trial design — anyone have experience?

MeganSA_TX Tue, Jan 9, 2024 at 10:31 AM 18 replies 2,325 viewsPage 4 of 4
MeganSA_TX
Member
634
2,890
Jun 2024
San Antonio, TX
Jan 9, 2024 at 4:11 PM#16

OP here — wow, did not expect this much response! Thank you all for the thoughtful replies on SURPASS-CVOT tirzepatide.

To answer PharmacoVig_BOS: I started tracking everything in a spreadsheet from day 1.

Quick update: I will post a proper update thread soon. Thanks again for the evidence-based discussion — this is exactly why I posted in a science-based community. 🙏

48 17PharmD_Rodriguez, julia.endo, JessicaM_2024 and 45 others
Reply Quote Save Share Report
FDA_TrackerJim
Senior Member
1,567
7,890
Feb 2024
Rockville, MD
Jan 9, 2024 at 4:28 PM#17

Adding my data to this SURPASS-CVOT tirzepatide discussion:

MetricBaselineMonth 4Month 8
Weight266 lbs236 lbs211 lbs
A1C7.0%6.2%5.4%
hsCRP5.03.00.8

Protocol: Tirzepatide 15mg/wk, resistance training 3x/wk, protein 1.3g/kg/day.

48 3Admin, Dr.Martinez, mike_mod and 45 others
Reply Quote Save Share Report
Dr.MetabolicMD
VIP Member
2,345
16,789
Jan 2024
Rochester, MN
Jan 9, 2024 at 4:45 PM#18

Subscribing to this thread. SURPASS-CVOT tirzepatide is exactly what I've been researching. 🙏

Last edited: Jan 9, 2024 at 6:45 PM
19 16HealthEcon_DC, PedsEndoPhilly, SleepDoc_PDX and 16 others
Reply Quote Save Share Report
Dr.SurgeonPGH
Senior Member
1,345
6,789
Mar 2024
Pittsburgh, PA
Jan 9, 2024 at 5:02 PM#19

Slightly tangential to SURPASS-CVOT tirzepatide but WendyG_ATL reminded me — has anyone else noticed changes in their alcohol tolerance?

I know it is not exactly on-topic but it seems related enough to ask here rather than starting a new thread. Apologies if this has been covered — I did search first.

Last edited: Jan 9, 2024 at 8:02 PM
45 14RickReta_CO, PharmHunterJen, TomTeleRx and 42 others
Reply Quote Save Share Report
hans_munich
Member
534
2,345
Jul 2024
Munich, DE
Jan 9, 2024 at 5:19 PM#20

+1 to MeganSA_TX. Especially the point about "Thank you all for the thoughtful replies..." — I have seen the same in my own experience with SURPASS-CVOT tirzepatide.

35 23emma_london, tammy_FL, Dr.LipidDallas and 32 others
Reply Quote Save Share Report

Similar Threads

SUSTAIN-6 to SELECT — the cardiovascular evidence timeline14 replies
GLP-1 and insulin resistance — HOMA-IR improvement data17 replies
Metabolic syndrome reversal criteria — how GLP-1 addresses all 55 replies
A1C target achievement rates — sema vs tirz comparison8 replies
SURPASS-CVOT: tirzepatide cardiovascular outcomes trial design3 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register